Pfizer teams up with Sangamo in hemophilia A
In a potential $545mm deal, Sangamo Therapeutics Inc. is partnering its hemophilia gene therapy programs, including Phase I-ready SB525, with Pfizer Inc.
- Gene Therapy, Cell Therapy
- Large Molecule
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.